Search

End stage glaucoma management

A 48-year-old female has had multiple drug treatment for glaucoma and is still losing field of vision. How do you manage this over time? This patient is at high-risk for going blind and should be managed aggressively to protect remaining...

Neurofibromatosis type 2 – diagnosis, features and MDT approach

NF2 is a genetic condition caused by mutation in a single gene (NF2 gene) on chromosome 22. The NF2 gene provides instructions to produce a protein called merlin, also known as schwannomin. This protein functions as a tumour suppressor, preventing...

Demyelinating optic neuropathy

Introduction Optic neuritis (ON) is an inflammatory process affecting the optic nerve. After glaucoma, it is the most common optic neuropathy affecting patients under the age of 50. The usual presentation of typical ON is unilateral subacute loss of vision...

The results of the last survey Oct22

I thank everyone for their time in responding to this edition’s survey questions. The first question relates to an issue I have previously discussed around consent for second eye cataract surgery. I touch on this point again for two reasons....

The results of the last survey Apr24

It has been a few years now since we started these surveys and I continue to be amazed by the variance in our practice. As a patient, I think I would expect there to be more consistency and evidence-based practice....

High-stakes scenarios in retinal vein occlusion: A survey of medico-legal implications

Central retinal vein occlusion (CRVO) is the second most common retinal vascular disease after diabetic retinopathy, and its clinical complexity often intersects with medico-legal scrutiny [1]. Missteps in timely diagnosis, inadequate follow-up or poor documentation can lead to patient harm...